GHK-Cu: topical evidence and injection limits

Check the copper complex and route

GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine, also called copper tripeptide-1 or prezatide copper. Copper-free GHK is a different material. A cream, wound gel, microneedle product, and injection do not deliver the same exposure.

What the studies measured

A laboratory experiment found increased collagen synthesis in cultured fibroblasts. That is a mechanism finding, not evidence of a clinical benefit.

A randomized study compared skin-care regimens with or without topical GHK-Cu after CO2 laser resurfacing. Thirteen patients completed follow-up. At 12 weeks, patients using GHK-Cu reported greater skin-quality improvement. Objective and blinded assessments found no between-group advantage in redness resolution, wrinkles, or overall skin quality.

The abstract does not establish a reproducible application schedule for other products. A separate 2026 registry record, NCT07437586, describes a planned daily topical wound-gel comparison with vehicle for two weeks. It has no posted results and does not validate a home wound-care protocol. Neither record tests a systemic injection regimen.

Regulatory categories do not prove benefit

No FDA-approved GHK-Cu drug was identified at this review. FDA lists non-injectable GHK-Cu in 503A Category 1, under evaluation. Injectable routes are excluded. FDA separately identifies injectable safety uncertainties, including possible immune reactions from aggregates or impurities.

Record the formulation your plan actually names

The cited evidence does not establish a validated injectable human regimen. If a clinician has supplied a plan, record the copper-bound identity, complete product name, vehicle or formulation, concentration, route, application site, prescribed amount and unit, timing, and duration. Keep the intended outcome and the clinician's review and stopping instructions. Do not turn a cell-culture result or topical study into an injection schedule.